EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis - Pharmaceutical Technology

Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market. Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market. Among participants who remained on treatment, weight loss at week 68 was substantial across all groups, with no clear linear relationship with dose. Credit: New Africa/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news…

Source: Pharmaceutical Technology